Patient Track

28th November – 08:30 – 09:45 – Session I
Education Track

Biomarkers Health Literacy

Biomarkers are still largely unknown by cancer patients and are insufficiently used by physicians.

The latter use diagnostic tests to clarify and support their clinical decision making and poor patient knowledge, difficulties in reimbursement and lack of existing biomarkers in some European countries are an obstacle to improving cancer patients’ clinical outcomes.

Here we will discuss:

  • What are Biomarkers?
  • Information to Patient
  • Recommendations for Policy Maker
  • What can be Done?
  • Increase Biomarker Literacy.
  • Improve Access.
  • Adapting the Regulatory Framework.


Nuria Malats

Nuria Malats

Group Leader, Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre, Madrid, Spain


Academia: Biomarkers Overview

 Nicola Normanno

Prof Nicola Normanno

Istituto Nazionale Tumori, Napoli

 Lydia Makaroff

Lydia Makaroff

Director, ECPC, Belgium, Civil society: Personalised Medicine Awareness Month

Tonu Esku

Tonu Esko

Deputy Director of Research, Estonian Biobank, Estonian Genome Center, University of Tartu, Estonia

Ilona Schelle

Ilona Schelle


Industry: improving the immuno-oncology lexicon


Paul Naish

AstraZeneca, Belgium